Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 28;399(10340):2047-2064.
doi: 10.1016/S0140-6736(22)00478-0. Epub 2022 May 19.

Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis

You Li  1 , Xin Wang  1 , Dianna M Blau  2 , Mauricio T Caballero  3 , Daniel R Feikin  4 , Christopher J Gill  5 , Shabir A Madhi  6 , Saad B Omer  7 , Eric A F Simões  8 , Harry Campbell  9 , Ana Bermejo Pariente  9 , Darmaa Bardach  10 , Quique Bassat  11 , Jean-Sebastien Casalegno  12 , Giorgi Chakhunashvili  13 , Nigel Crawford  14 , Daria Danilenko  15 , Lien Anh Ha Do  16 , Marcela Echavarria  17 , Angela Gentile  18 , Aubree Gordon  19 , Terho Heikkinen  20 , Q Sue Huang  21 , Sophie Jullien  22 , Anand Krishnan  23 , Eduardo Luis Lopez  24 , Joško Markić  25 , Ainara Mira-Iglesias  26 , Hannah C Moore  27 , Jocelyn Moyes  28 , Lawrence Mwananyanda  5 , D James Nokes  29 , Faseeha Noordeen  30 , Evangeline Obodai  31 , Nandhini Palani  32 , Candice Romero  33 , Vahid Salimi  34 , Ashish Satav  35 , Euri Seo  36 , Zakhar Shchomak  37 , Rosalyn Singleton  38 , Kirill Stolyarov  15 , Sonia K Stoszek  39 , Anne von Gottberg  40 , Danielle Wurzel  41 , Lay-Myint Yoshida  42 , Chee Fu Yung  43 , Heather J Zar  44 ; Respiratory Virus Global Epidemiology Network; Harish Nair  45 ; RESCEU investigators
Collaborators, Affiliations
Review

Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis

You Li et al. Lancet. .

Abstract

Background: Respiratory syncytial virus (RSV) is the most common cause of acute lower respiratory infection in young children. We previously estimated that in 2015, 33·1 million episodes of RSV-associated acute lower respiratory infection occurred in children aged 0-60 months, resulting in a total of 118 200 deaths worldwide. Since then, several community surveillance studies have been done to obtain a more precise estimation of RSV associated community deaths. We aimed to update RSV-associated acute lower respiratory infection morbidity and mortality at global, regional, and national levels in children aged 0-60 months for 2019, with focus on overall mortality and narrower infant age groups that are targeted by RSV prophylactics in development.

Methods: In this systematic analysis, we expanded our global RSV disease burden dataset by obtaining new data from an updated search for papers published between Jan 1, 2017, and Dec 31, 2020, from MEDLINE, Embase, Global Health, CINAHL, Web of Science, LILACS, OpenGrey, CNKI, Wanfang, and ChongqingVIP. We also included unpublished data from RSV GEN collaborators. Eligible studies reported data for children aged 0-60 months with RSV as primary infection with acute lower respiratory infection in community settings, or acute lower respiratory infection necessitating hospital admission; reported data for at least 12 consecutive months, except for in-hospital case fatality ratio (CFR) or for where RSV seasonality is well-defined; and reported incidence rate, hospital admission rate, RSV positive proportion in acute lower respiratory infection hospital admission, or in-hospital CFR. Studies were excluded if case definition was not clearly defined or not consistently applied, RSV infection was not laboratory confirmed or based on serology alone, or if the report included fewer than 50 cases of acute lower respiratory infection. We applied a generalised linear mixed-effects model (GLMM) to estimate RSV-associated acute lower respiratory infection incidence, hospital admission, and in-hospital mortality both globally and regionally (by country development status and by World Bank Income Classification) in 2019. We estimated country-level RSV-associated acute lower respiratory infection incidence through a risk-factor based model. We developed new models (through GLMM) that incorporated the latest RSV community mortality data for estimating overall RSV mortality. This review was registered in PROSPERO (CRD42021252400).

Findings: In addition to 317 studies included in our previous review, we identified and included 113 new eligible studies and unpublished data from 51 studies, for a total of 481 studies. We estimated that globally in 2019, there were 33·0 million RSV-associated acute lower respiratory infection episodes (uncertainty range [UR] 25·4-44·6 million), 3·6 million RSV-associated acute lower respiratory infection hospital admissions (2·9-4·6 million), 26 300 RSV-associated acute lower respiratory infection in-hospital deaths (15 100-49 100), and 101 400 RSV-attributable overall deaths (84 500-125 200) in children aged 0-60 months. In infants aged 0-6 months, we estimated that there were 6·6 million RSV-associated acute lower respiratory infection episodes (4·6-9·7 million), 1·4 million RSV-associated acute lower respiratory infection hospital admissions (1·0-2·0 million), 13 300 RSV-associated acute lower respiratory infection in-hospital deaths (6800-28 100), and 45 700 RSV-attributable overall deaths (38 400-55 900). 2·0% of deaths in children aged 0-60 months (UR 1·6-2·4) and 3·6% of deaths in children aged 28 days to 6 months (3·0-4·4) were attributable to RSV. More than 95% of RSV-associated acute lower respiratory infection episodes and more than 97% of RSV-attributable deaths across all age bands were in low-income and middle-income countries (LMICs).

Interpretation: RSV contributes substantially to morbidity and mortality burden globally in children aged 0-60 months, especially during the first 6 months of life and in LMICs. We highlight the striking overall mortality burden of RSV disease worldwide, with one in every 50 deaths in children aged 0-60 months and one in every 28 deaths in children aged 28 days to 6 months attributable to RSV. For every RSV-associated acute lower respiratory infection in-hospital death, we estimate approximately three more deaths attributable to RSV in the community. RSV passive immunisation programmes targeting protection during the first 6 months of life could have a substantial effect on reducing RSV disease burden, although more data are needed to understand the implications of the potential age-shifts in peak RSV burden to older age when these are implemented.

Funding: EU Innovative Medicines Initiative Respiratory Syncytial Virus Consortium in Europe (RESCEU).

PubMed Disclaimer

Conflict of interest statement

Declaration of interests

YL reports grants from Wellcome Trust and WHO outside the submitted work. MTC reports grants from the Bill & Melinda Gates Foundation related to the submitted work, grants from MITS Surveillance Alliance, and support for attending the RSVVW meeting from ReSViNET outside the submitted work. SAM reports grants from Pfizer, Minervax, GSK, the Gates Foundation, and South African Medical Research Council; honoraria from the Gates Foundation; and participation on data safety monitoring boards for PATH and CAPRISA, outside the submitted work. SBO reports grants from the Gates Foundation outside the submitted work. EAFS reports grants, personal fees, and travel fees from AstraZeneca, Merck, Regeneron, Pfizer, and Roche; consultation, lecture fees, travel support, and data and safety monitoring board fees from AbbVie; data and safety monitoring board fees from GSK; consultation fees from Alere; grants from Johnson & Johnson; and grants and travel support from Novavax outside the submitted work. HC reports grants from the Gates Foundation outside the submitted work. AGo reports grants from the National Institute of Allergy and Infectious Diseases and Centers for Disease Control and Prevention (CDC) related to the submitted work and participation on an advisory board for Janssen outside the submitted work. TH reports personal fees from Janssen and Sanofi Pasteur outside the submitted work. AK reports grants from CDC and honoraria from CDC and WHO outside the submitted work. AM-I reports grants from FISABIO-Public Health, Sanofi Pasteur, and CIBER-ESP (ISCIII) related to the submitted work, honoraria from MSD as a speaker in a vaccine research course, and travel grants for attending meetings sponsored by Sanofi, outside the submitted work. HCM reports grants from National Health and Medical Research Council related to the submitted work and honoraria from MSD for participation on an expert input forum outside the submitted work. DJN reports grants from Wellcome Trust related to the submitted work. EO reports receipt of PhD scholarship from DAAD (German Academic Exchange Service) Government of Ghana scholarship outside the submitted work. CR reports grants from CDC in collaboration with US Naval Medical Research Unit No6 related to the submitted work and grants from South America Influenza Initiative outside the submitted work. AS reports grants from University of Colorado outside the submitted work. RS reports grants from Merck outside the submitted work. SKS reports salaries from GSK for working on the data abstraction, leading the prospective cohort study from which the data were abstracted, and for providing input for the manuscript development related to the submitted work and stock in GSK outside the submitted work. AvG reports grants from CDC outside the submitted work. DW reports grants from Murdoch Children’s Research Institute related to the submitted work and honoraria from MSD for participation on an expert input forum outside the submitted work. L-MY reports grants from Japan Agency for Medical Research and Development related to the submitted work and honoraria for a lecture from MSD KK. HJZ reports grants from the Gates Foundation, South African Medical Research Council, National Institutes for Health, and AstraZeneca and participation on WHO Technical Advisory Group with no payment, outside the submitted work. HN reports grants from the Innovative Medicines Initiative related to the submitted work and consulting fees from the Gates Foundation, Pfizer, and Sanofi; honoraria from AbbVie; support from Sanofi for attending meetings; and participation on advisory boards from Sanofi, Janssen, Novavax, Reviral, Resvinet, and WHO outside the submitted work.

Figures

Figure 1
Figure 1. Approaches for estimation of global RSV morbidity and mortality in children aged 0–60 months
Boxes with solid borders are main analyses. Boxes with dashed borders are sensitivity analyses. RSV=respiratory syncytial virus. ALRI=acute lower respiratory infection. GLMM=generalised linear mixed-effects model. hCFR= in-hospital case fatality ratio. *Details in the appendix (p 12). †Details in the appendix (p 13). ‡Details in the appendix (p 17). §Details in the appendix (p 19).
Figure 2
Figure 2. Burden of RSV-associated ALRI in infants aged 0–6 months in LMICs by severity and outcome including burden on health-care services
ALRI=acute lower respiratory infection. CFR=case fatality ratio. LMICs=low and middle income countries. RSV=respiratory syncytial virus. UR=uncertainty range.
See this image and copyright information in PMC

Comment in

References

    1. O’Brien KL, Baggett HC, Brooks WA, et al. Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study. Lancet. 2019;394:757–79. - PMC - PubMed
    1. Bénet T, Sánchez Picot V, Messaoudi M, et al. Microorganisms associated with pneumonia in children <5 years of age in developing and emerging countries: the GABRIEL pneumonia multicenter, prospective, case-control study. Clin Infect Dis. 2017;65:604–12. - PMC - PubMed
    1. Shi T, McAllister DA, O’Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390:946–58. - PMC - PubMed
    1. Srikantiah P, Vora P, Klugman KP. Assessing the full burden of respiratory syncytial virus in young infants in low- and middleincome countries: the importance of community mortality studies. Clin Infect Dis. 2021;73(suppl 3):S177–79. - PMC - PubMed
    1. Taylor AW, Blau DM, Bassat Q, et al. Initial findings from a novel population-based child mortality surveillance approach: a descriptive study. Lancet Glob Health. 2020;8:e909–19. - PMC - PubMed